Uliledlimab clinical trials
Also written TJ004309.
How each study uses uliledlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
TJ Biopharma Co., Ltd. (2) · I-Mab Biopharma US Limited (1) · Tracon Pharmaceuticals Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses uliledlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase I/II Study of TJ004309 for Advanced Solid TumorCompletedPhase 1/2TJ Biopharma Co., Ltd.NCT04322006Written as TJ004309
- A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung CancerActive, not recruitingPhase 2/3TJ Biopharma Co., Ltd.NCT06984588Written as Uliledlimab
- A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid TumorsCompletedPhase 2I-Mab Biopharma US LimitedNCT05001347Written as TJ004309
- Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic CancerStatus unknownPhase 1Tracon Pharmaceuticals Inc.NCT03835949Written as TJ004309
Given beside what is tested · 1 — uliledlimab is usual care or a partner of the new treatment
Codes
What other systems call uliledlimab · ClinicalTrials.gg INT014708
- UNII (FDA) 3OX1DBR75GULILEDLIMABOne source FDA
- NCI Thesaurus C159168UliledlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3OX1DBR75G | ULILEDLIMAB | One source FDA |
| NCI Thesaurus | C159168 | Uliledlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.